vs
Side-by-side financial comparison of ALBANY INTERNATIONAL CORP (AIN) and Axsome Therapeutics, Inc. (AXSM). Click either name above to swap in a different company.
ALBANY INTERNATIONAL CORP is the larger business by last-quarter revenue ($321.2M vs $191.2M, roughly 1.7× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 12.0%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 1.2%).
Albany International Corp is a global advanced materials and industrial technology company. It operates two core segments: Machine Clothing producing custom engineered fabrics for paper and other industrial manufacturing processes, and Engineered Composites developing high-performance composite components primarily for the aerospace and defense sectors, serving customers across North America, Europe, Asia and other global regions.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
AIN vs AXSM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $321.2M | $191.2M |
| Net Profit | $13.9M | — |
| Gross Margin | 31.1% | — |
| Operating Margin | 9.3% | -33.1% |
| Net Margin | 4.3% | — |
| Revenue YoY | 12.0% | 57.4% |
| Net Profit YoY | -21.5% | — |
| EPS (diluted) | $0.56 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $191.2M | ||
| Q4 25 | $321.2M | $196.0M | ||
| Q3 25 | $261.4M | $171.0M | ||
| Q2 25 | $311.4M | $150.0M | ||
| Q1 25 | $288.8M | $121.5M | ||
| Q4 24 | $286.9M | $118.8M | ||
| Q3 24 | $298.4M | $104.8M | ||
| Q2 24 | $332.0M | $87.2M |
| Q1 26 | — | — | ||
| Q4 25 | $13.9M | $-28.6M | ||
| Q3 25 | $-97.8M | $-47.2M | ||
| Q2 25 | $9.2M | $-48.0M | ||
| Q1 25 | $17.4M | $-59.4M | ||
| Q4 24 | $17.7M | $-74.9M | ||
| Q3 24 | $18.0M | $-64.6M | ||
| Q2 24 | $24.6M | $-79.3M |
| Q1 26 | — | — | ||
| Q4 25 | 31.1% | — | ||
| Q3 25 | -19.1% | — | ||
| Q2 25 | 31.3% | — | ||
| Q1 25 | 33.4% | — | ||
| Q4 24 | 31.5% | — | ||
| Q3 24 | 30.3% | — | ||
| Q2 24 | 33.9% | — |
| Q1 26 | — | -33.1% | ||
| Q4 25 | 9.3% | -13.8% | ||
| Q3 25 | -44.6% | -27.0% | ||
| Q2 25 | 7.2% | -24.5% | ||
| Q1 25 | 9.8% | -46.9% | ||
| Q4 24 | 8.5% | -61.1% | ||
| Q3 24 | 8.4% | -59.8% | ||
| Q2 24 | 12.9% | -89.5% |
| Q1 26 | — | — | ||
| Q4 25 | 4.3% | -14.6% | ||
| Q3 25 | -37.4% | -27.6% | ||
| Q2 25 | 2.9% | -32.0% | ||
| Q1 25 | 6.0% | -48.9% | ||
| Q4 24 | 6.2% | -63.1% | ||
| Q3 24 | 6.0% | -61.7% | ||
| Q2 24 | 7.4% | -91.0% |
| Q1 26 | — | — | ||
| Q4 25 | $0.56 | $-0.55 | ||
| Q3 25 | $-3.37 | $-0.94 | ||
| Q2 25 | $0.31 | $-0.97 | ||
| Q1 25 | $0.56 | $-1.22 | ||
| Q4 24 | $0.57 | $-1.54 | ||
| Q3 24 | $0.57 | $-1.34 | ||
| Q2 24 | $0.79 | $-1.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $112.3M | $305.1M |
| Total DebtLower is stronger | $455.7M | $70.0M |
| Stockholders' EquityBook value | $726.2M | — |
| Total Assets | $1.7B | $713.6M |
| Debt / EquityLower = less leverage | 0.63× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $305.1M | ||
| Q4 25 | $112.3M | $322.9M | ||
| Q3 25 | $108.3M | $325.3M | ||
| Q2 25 | $106.7M | $303.0M | ||
| Q1 25 | $119.4M | $300.9M | ||
| Q4 24 | $115.3M | $315.4M | ||
| Q3 24 | $127.2M | $327.3M | ||
| Q2 24 | $116.4M | $315.7M |
| Q1 26 | — | $70.0M | ||
| Q4 25 | $455.7M | — | ||
| Q3 25 | $480.6M | — | ||
| Q2 25 | $444.7M | — | ||
| Q1 25 | $416.4M | — | ||
| Q4 24 | $318.5M | — | ||
| Q3 24 | $362.2M | — | ||
| Q2 24 | $377.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | $726.2M | $88.3M | ||
| Q3 25 | $739.3M | $73.7M | ||
| Q2 25 | $888.6M | $73.1M | ||
| Q1 25 | $900.0M | $53.2M | ||
| Q4 24 | $943.5M | $57.0M | ||
| Q3 24 | $991.0M | $92.9M | ||
| Q2 24 | $967.5M | $102.9M |
| Q1 26 | — | $713.6M | ||
| Q4 25 | $1.7B | $689.8M | ||
| Q3 25 | $1.7B | $669.3M | ||
| Q2 25 | $1.7B | $639.8M | ||
| Q1 25 | $1.7B | $596.7M | ||
| Q4 24 | $1.6B | $568.5M | ||
| Q3 24 | $1.8B | $561.5M | ||
| Q2 24 | $1.8B | $548.2M |
| Q1 26 | — | — | ||
| Q4 25 | 0.63× | — | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | 0.46× | — | ||
| Q4 24 | 0.34× | — | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.39× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $73.7M | — |
| Free Cash FlowOCF − Capex | $51.4M | — |
| FCF MarginFCF / Revenue | 16.0% | — |
| Capex IntensityCapex / Revenue | 6.9% | — |
| Cash ConversionOCF / Net Profit | 5.31× | — |
| TTM Free Cash FlowTrailing 4 quarters | $82.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $73.7M | $-18.7M | ||
| Q3 25 | $43.9M | $1.0M | ||
| Q2 25 | $32.7M | $-32.4M | ||
| Q1 25 | $2.1M | $-43.4M | ||
| Q4 24 | $78.5M | $-26.2M | ||
| Q3 24 | $47.0M | $-18.6M | ||
| Q2 24 | $83.4M | $-30.1M |
| Q1 26 | — | — | ||
| Q4 25 | $51.4M | $-18.7M | ||
| Q3 25 | $25.9M | $988.0K | ||
| Q2 25 | $18.8M | $-32.4M | ||
| Q1 25 | $-13.5M | $-43.7M | ||
| Q4 24 | $60.2M | $-26.2M | ||
| Q3 24 | $31.6M | $-18.7M | ||
| Q2 24 | $63.6M | $-30.2M |
| Q1 26 | — | — | ||
| Q4 25 | 16.0% | -9.6% | ||
| Q3 25 | 9.9% | 0.6% | ||
| Q2 25 | 6.0% | -21.6% | ||
| Q1 25 | -4.7% | -36.0% | ||
| Q4 24 | 21.0% | -22.1% | ||
| Q3 24 | 10.6% | -17.9% | ||
| Q2 24 | 19.2% | -34.6% |
| Q1 26 | — | — | ||
| Q4 25 | 6.9% | 0.0% | ||
| Q3 25 | 6.9% | 0.0% | ||
| Q2 25 | 4.5% | 0.0% | ||
| Q1 25 | 5.4% | 0.3% | ||
| Q4 24 | 6.4% | 0.0% | ||
| Q3 24 | 5.2% | 0.1% | ||
| Q2 24 | 6.0% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | 5.31× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.56× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 4.44× | — | ||
| Q3 24 | 2.61× | — | ||
| Q2 24 | 3.39× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIN
| Transferred At Point In Time | $176.5M | 55% |
| Engineered Composites Other | $99.3M | 31% |
| Engineered Composites ASC | $44.5M | 14% |
| Transferred Over Time | $1.0M | 0% |
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
